JP2020519645A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519645A5
JP2020519645A5 JP2019562579A JP2019562579A JP2020519645A5 JP 2020519645 A5 JP2020519645 A5 JP 2020519645A5 JP 2019562579 A JP2019562579 A JP 2019562579A JP 2019562579 A JP2019562579 A JP 2019562579A JP 2020519645 A5 JP2020519645 A5 JP 2020519645A5
Authority
JP
Japan
Prior art keywords
hadsc
pellet
tissue
adipose tissue
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019562579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2018/050523 external-priority patent/WO2018211498A1/en
Publication of JP2020519645A publication Critical patent/JP2020519645A/ja
Publication of JP2020519645A5 publication Critical patent/JP2020519645A5/ja
Pending legal-status Critical Current

Links

JP2019562579A 2017-05-15 2018-05-14 脂肪組織由来幹細胞による多発性硬化症の治療 Pending JP2020519645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506006P 2017-05-15 2017-05-15
US62/506,006 2017-05-15
PCT/IL2018/050523 WO2018211498A1 (en) 2017-05-15 2018-05-14 Treatment of multiple sclerosis with adipose-derived stem cells

Publications (2)

Publication Number Publication Date
JP2020519645A JP2020519645A (ja) 2020-07-02
JP2020519645A5 true JP2020519645A5 (OSRAM) 2021-05-06

Family

ID=64274150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562579A Pending JP2020519645A (ja) 2017-05-15 2018-05-14 脂肪組織由来幹細胞による多発性硬化症の治療

Country Status (8)

Country Link
US (1) US11510946B2 (OSRAM)
EP (1) EP3624816A4 (OSRAM)
JP (1) JP2020519645A (OSRAM)
CN (1) CN110573170A (OSRAM)
AU (1) AU2018270396B2 (OSRAM)
CA (1) CA3062123A1 (OSRAM)
IL (1) IL269893B2 (OSRAM)
WO (1) WO2018211498A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
IL272145A (en) 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue
CN115624570A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗结缔组织疾病药物中的应用
CN115624571A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗硬皮病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
PT1248643E (pt) 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US7682803B2 (en) 2005-10-13 2010-03-23 Anthrogenesis Corporation Immunomodulation using placental stem cells
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
ES2397836T3 (es) 2003-01-21 2013-03-11 Yeda Research And Development Co., Ltd. Copolímero 1 para el tratamiento de enfermedades inflamatorias del intestino
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
EP1827108B1 (en) 2004-11-29 2015-04-08 Yeda Research And Development Co., Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
JP4654015B2 (ja) 2004-12-08 2011-03-16 京セラ株式会社 カメラ装置
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
RS57083B1 (sr) 2006-11-03 2018-06-29 Multiple Sclerosis Res Center Of New York Mezenhimske matične ćelije dobijene iz koštane srži kao izvor progenitora neuralnih ćelija
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
AU2009227022B2 (en) * 2008-03-19 2014-07-03 Cryo-Save Ag Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
ES2688945T3 (es) 2008-05-28 2018-11-07 Ramot At Tel-Aviv University Ltd. Células madre mesenquimales para el tratamiento de enfermedades del SNC
WO2010014990A2 (en) 2008-08-01 2010-02-04 The Board Of Trustees Of The University Of Illinois Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
US20110274667A1 (en) 2008-10-17 2011-11-10 Baxter Healthcare S.A. Methods for obtaining cell populations from adipose tissue
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
CN107007626A (zh) 2009-07-09 2017-08-04 蒂盖尼克斯公司 用于细胞治疗的方法和组合物
EP2482761A4 (en) 2009-09-30 2014-03-19 Brigham & Womens Hospital TISSUE TRANSPLANT COMPOSITIONS AND METHOD FOR THEIR USE
CA2784394C (en) 2010-01-04 2016-12-13 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2536825B1 (en) 2010-02-18 2024-03-27 Osiris Therapeutics, Inc. Immunocompatible amniotic membrane products
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
DK3546569T3 (da) 2011-09-23 2021-07-12 Cell Ideas Pty Ltd Terapeutiske midler med anvendelse af fedtceller og cellesekreter
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US20150030662A1 (en) 2012-03-12 2015-01-29 National University Of Singapore Generation of Brown Adipose Tissue (BAT) from Mesenchymal Cells
CN104130975B (zh) * 2013-05-03 2018-07-17 上海市东方医院 人源脂肪干细胞来源的神经元样细胞及其制备方法和应用
US20150216908A1 (en) 2014-02-06 2015-08-06 Steminent Biotherapeutics Inc. Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation
WO2015120388A1 (en) * 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
AU2017218143B2 (en) 2016-02-12 2023-08-03 Cell Care Therapeutics, Inc. Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Similar Documents

Publication Publication Date Title
JP2020519645A5 (OSRAM)
Sun et al. Single-cell RNA-seq highlights heterogeneity in human primary Wharton’s jelly mesenchymal stem/stromal cells cultured in vitro
Nagamura-Inoue et al. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility
Mildmay-White et al. Cell surface markers on adipose-derived stem cells: a systematic review
Sivasubramaniyan et al. Phenotypic and functional heterogeneity of human bone marrow–and amnion‐derived MSC subsets
Otsuru et al. Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device
Keating Mesenchymal stromal cells: new directions
He et al. Human cardiac stem cells isolated from atrial appendages stably express c-kit
Baer et al. Adipose‐derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity
Corselli et al. Perivascular ancestors of adult multipotent stem cells
EP2975118B1 (en) Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
Goligorsky Endothelial progenitor cells: from senescence to rejuvenation
JP2011529706A5 (OSRAM)
Bogdanova et al. Characterization of human adipose-derived stem cells cultured in autologous serum after subsequent passaging and long term cryopreservation
CN109234229B (zh) 从胎盘血管分离间充质干细胞的方法和所用消化酶组合物
Zhou et al. Amniotic fluid-derived mesenchymal stem cells: characteristics and therapeutic applications
Song et al. Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion
Yen-Shun et al. Mesenchymal stem cell: considerations for manufacturing and clinical trials on cell therapy product
US20240115618A1 (en) Treatment of diseases of endothelial dysfunction and inflammation
CN103421739B (zh) 一种高效分离脐带间充质干细胞的方法
Hosseini et al. Lupus mice derived mesenchymal stromal cells: Beneficial or detrimental on SLE disease outcome
CN105025927B (zh) 人cd34阴性祖细胞保护血管内皮细胞层避免免疫介导的细胞毒性反应
Jin et al. Stem Cell‐Based Cell Therapy for Glomerulonephritis
Li et al. Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review
Dhanasekaran et al. Unravelling the retention of proliferation and differentiation potency in extensive culture of human subcutaneous fat‐derived mesenchymal stem cells in different media